Abbott received FDA De Novo authorization for Libre Duo 10 Day, the first wearable device that continuously monitors glucose and detects rising ketone levels, which can signal diabetic ketoacidosis. This regulatory milestone sets Abbott apart in diabetes care, though the stock remains below last year's levels. The device is planned for U.S. launch in late 2026, targeting patients aged 2 and older, with future integration into insulin pumps expected to boost its market impact. The stock's re-rating depends on successful commercial rollout and expanded insurance reimbursement, especially for Type 2 diabetes coverage among Medicare beneficiaries.
Abbott has received CE Mark approval for its Amulet 360 Left Atrial Appendage Occluder, a next-generation device designed to reduce stroke risk in patients with atrial fibrillation (AFib) by sealing the heart's left atrial appendage (LAA). The device...
Abbott has received FDA authorization for its Libre Duo 10 Day system, the world's first biowearable device that continuously monitors both glucose and ketone levels. This innovation helps people with diabetes detect rising ketones early, which can p...
Retirees choosing between Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Real Estate ETF (VNQ) face a clear divergence due to the current high interest rate environment. SCHD, focused on dividend-paying companies with strong cash flow, has outpe...
